Article

Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 Study

2022-04-25

Abstract excerpt

Background COVID-19 Convalescent Plasma (CCP) was an early and widely adopted putative therapy for severe COVID-19. Results from randomized control trials and observational studies have failed to demonstrate a clear therapeutic role for CCP for severe SARS-CoV-2 infection. Underlying these inconclusive findings is a broad heterogeneity in the concentrations of neutralizing antibodies (nAb) between different CCP do...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 244e5c3e-36e8-5d83-baca-585985da707c
DOI: 10.2139/ssrn.4092959

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 StudyDOI 10.2139/ssrn.4092959Read

Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 studySemantic proximity Read

A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19Semantic proximity Read

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent PlasmaSemantic proximity Read

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacySemantic proximity Read

COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized TrialsSemantic proximity Read

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceSemantic proximity Read

Association of Convalescent Plasma Treatment with Reduced Mortality and Improved Clinical Trajectory in Patients Hospitalized with COVID-19 in the Community SettingSemantic proximity Read

A Role for Nucleocapsid-Specific Antibody Function in COVID-19 Convalescent Plasma TherapySemantic proximity Read

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity Read

Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralizationSemantic proximity Read

Efficacy and safety of convalescent plasma therapy for severe COVID-19 patients：case series study and literature reviewSemantic proximity Read

Functional Antibodies in COVID-19 Convalescent PlasmaSemantic proximity Read